Litigation Details for AbbVie Inc. v. Alembic Pharmaceuticals Limited (D. Del. 2024)

AbbVie Inc. v. Alembic Pharmaceuticals Limited (D. Del. 2024)

Docket		Date Filed	2024-03-29
Court	District Court, D. Delaware	Date Terminated	2024-05-13
Cause	35:271 Patent Infringement	Assigned To	Stephanos Bibas
Jury Demand	None	Referred To
Patents	10,617,695; 8,664,215
Link to Docket	External link to docket

Details for AbbVie Inc. v. Alembic Pharmaceuticals Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-03-29				External link to document

AbbVie v. Alembic (1:24-cv-00405) Litigation Summary, Patent/Orange Book Posture, and Generic Launch Risk Analysis

Last updated: July 18, 2026

AbbVie Inc. v. Alembic Pharmaceuticals Limited, case number 1:24-cv-00405, is a 2024 Hatch-Waxman patent infringement action tied to an AbbVie small-molecule/brand product facing Alembic Paragraph IV litigation. The record and party-caption identify the matter as a generic entry dispute rather than an FDA regulatory proceeding. A complete litigation summary with specific patents-in-suit, claims asserted, filing sequence (complaint, answer, Markman, trial), claim construction outcomes, injunction/settlement terms, and status (dismissed, stayed, or active) requires docket-specific content that is not provided in the prompt.

What is AbbVie v. Alembic Pharmaceuticals Limited (1:24-cv-00405) and why does it matter for generic entry?

Direct answer: The case is a Hatch-Waxman patent infringement dispute brought by AbbVie against Alembic, typically triggered by Alembic’s ANDA submission and Paragraph IV certifications against patents listed in the applicable FDA Orange Book.

What disputes are usually at issue in this case type

• Infringement: Alembic’s ANDA product alleged to infringe one or more AbbVie patents.
• Validity: Alembic typically challenges validity (anticipation/obviousness, written description, enablement, indefiniteness).
• Exclusivity timing: The parties litigate around which patents can block approval and which are no longer enforceable due to expiration or terminal disclaimer.

What business outcomes hinge on the docket

• Automatic 30-month stay can delay FDA approval pending litigation, depending on whether and when the suit was filed relative to ANDA notice dates.
• Settlement can shift the generic launch date and implement license terms.
• Final court rulings on infringement and validity can either clear the lane for generic approval or extend blocking protection.

Which product and patents are asserted in AbbVie v. Alembic (1:24-cv-00405)?

Direct answer: The prompt does not include the drug name, ANDA number, FDA NDA/Orange Book listing, or the patents-in-suit. Without that, a precise patent-by-patent infringement and invalidity analysis cannot be completed.

What is required for a litigation-grade patent map (not present in the prompt)

A complete analysis depends on the complaint’s:

• Patents-in-suit list (US patent numbers and listed expiration dates)
• Claim charts / infringement theory
• Ateempts to design-around (specifically alleged ANDA changes)
• Validity assertions (anticipation references, obviousness combinations, IPR estoppels if any)
• Relief sought (injunction scope, damages, attorneys’ fees)

Typical litigation artifacts that must be cited

• Complaint (Doc. __)
• Answer (Doc. __)
• Rule 16 scheduling order (Doc. __)
• Markman order (Doc. __)
• Claim construction hearing transcript and order
• Daubert orders (if any)
• Summary judgment opinions (if any)
• Dismissal/stay/termination orders

H2 alignment: What patents protect the brand in this dispute?

A correct answer requires the Orange Book patent family that AbbVie is enforcing against Alembic’s ANDA. The prompt does not identify:

• Active ingredient and dosage form
• Listed patents (composition, method-of-use, formulation, manufacturing)
• Whether the asserted patents include FDA 505(b)(2) or 505(b)(1) exclusivity listed entries

What is the Orange Book status in AbbVie v. Alembic (1:24-cv-00405)?

Direct answer: The Orange Book entry and the certifications (Paragraph IV vs. carve-outs) are not specified in the prompt, so an Orange Book status review cannot be generated accurately.

What an Orange Book status analysis must include

• NDA/ANDA linkage (NDA holder, application type)
• Patent list with:
  • Patent number
  • Patent expiry
  • Patent type (drug substance, drug product, method-of-use)
• Regulatory exclusivities (statutory and pediatric exclusivity, if applicable)
• Certification mapping:
  • Which patents were certified Paragraph IV
  • Whether any were certified “Section viii” or “not listed”

When does the case expire exclusivity and patent blocking effect?

Direct answer: Patent and exclusivity timelines cannot be stated without the patent numbers and the Orange Book listing tied to the ANDA dispute.

What a timing model needs to be litigation-accurate

• Earliest possible FDA approval date absent injunction
• Latest potential patent expiration among asserted and unasserted but blocking patents
• 30-month stay start and end dates (if applicable)
• Effect of:
  • Court invalidation or noninfringement findings
  • Dismissals by stipulation
  • Settlement-triggered “no earlier than” launch dates
  • Any terminal disclaimers

How strong is the patent estate in AbbVie v. Alembic (1:24-cv-00405)?

Direct answer: Strength cannot be assessed without identifying:

• The patents-in-suit
• Their claim scope and the accused ANDA product attributes
• The prior art and litigation history of the same families

Patent strength elements to be evaluated in a real assessment

• Claim construction likelihood for the asserted independent claims
• Prior art coverage relative to priority date
• Whether the asserted patents have:
  • surviving reexamination history
  • PTAB invalidation outcomes
  • prior Federal Circuit remands
• Enforceability issues:
  • inequitable conduct allegations
  • prosecution history estoppel
  • patent term adjustment effects

What generic entry risks exist for Alembic and other ANDA filers?

Direct answer: Generic entry risks depend on case outcomes and on whether Alembic is the first Paragraph IV filer for the relevant Orange Book patents.

Risk channels

• Blocking patents remain if AbbVie wins at claim construction or on infringement.
• Design-around effectiveness can reduce infringement exposure for method-of-use or formulation claims.
• Settlement offsets can cap at “authorized generic” timing or include market carve-outs.
• Other ANDA challengers may benefit if AbbVie loses on broad claims or if patents are invalidated.

What market participants typically track from the docket

• Whether Alembic obtained a stipulated stay pending appeal
• Whether the court entered a partial summary judgment narrowing asserted claims
• Whether the case is early-stage (complaint-to-answer only) or near decision/trial

What patent litigation procedural milestones typically occur in cases like 1:24-cv-00405?

Direct answer: A standard Hatch-Waxman schedule includes early case management and claim construction, then summary judgment and dispositive rulings. The actual milestone dates for this docket are not included in the prompt.

Procedural milestones to map to this case (must be docket-confirmed)

• Initial disclosure deadlines
• Markman
• Expert reports
• Summary judgment motions
• Pretrial conference
• Trial or bench decision
• Injunction/damages decision (if infringement is found)

Did AbbVie and Alembic reach a settlement or stipulation that changes launch timing?

Direct answer: Settlement status is not provided in the prompt, so no launch-delay or license terms can be stated.

Settlement outcomes that would be material in docket review

• Stipulated dismissal with “no earlier than” launch date
• License scope allowing certain manufacturing/labeling
• Retail pharmacy chain or wholesaler arrangements
• Stipulated permanent injunction for specific form strengths only

Is this case stayed, appealed, or consolidated with related actions?

Direct answer: The prompt does not provide any docket status indicator (stay/appeal/consolidation). Without docket events, an accurate posture cannot be produced.

What to check in docket history (not in prompt)

• Notices of appeal and Federal Circuit docket entries
• Mandate dates
• Rule 54(b) judgment applicability
• Parallel cases against other ANDA applicants

How does AbbVie’s litigation strategy in 1:24-cv-00405 compare with other AbbVie generic challenges?

Direct answer: No other AbbVie-vs-generic matters are listed in the prompt, so a comparative strategy analysis cannot be created from the provided information.

What a comparison would normally include

• Patent families used across multiple defendants
• Whether AbbVie relies on:
  • broad method-of-use claims
  • narrow formulation/device claims
  • composition-of-matter families
• Venue patterns (district court, judge, time-to-Markman)
• Settlement frequency and timing

---

Key Takeaways

• The case is a Hatch-Waxman patent infringement action brought by AbbVie against Alembic (1:24-cv-00405), tied to a generic ANDA entry challenge.
• The prompt does not include the asserted drug, ANDA/NDA linkage, Orange Book listing, or patents-in-suit, which prevents a litigation-grade summary of:
  • patents asserted and their expiration,
  • infringement/invalidity theories,
  • claim construction and dispositive outcomes,
  • settlement terms,
  • injunction or launch timing implications.

---

FAQs

1. What does a Paragraph IV notice typically trigger in AbbVie v. Alembic-type cases?
2. How do courts in Hatch-Waxman matters sequence claim construction and summary judgment?
3. What evidence does an ANDA defendant usually submit to contest infringement in method-of-use patent cases?
4. How does a settlement in an ANDA patent case affect “authorized generic” timing?
5. What Orange Book patent types most often drive blocking litigation against generic manufacturers?

---

References (APA)

1. Case caption provided in prompt: AbbVie Inc. v. Alembic Pharmaceuticals Limited, 1:24-cv-00405.